TABLE 1.
Comparison of results from HIV-1 assays
| Patient no. | Resulta from:
|
Degrees of underestimation (n-fold) by CTM assayb | HIV-1 subtypec | |||
|---|---|---|---|---|---|---|
| CTM | Cobas Amplicor Monitor HIV-1 v1.5 | Abbott RealTime HIV-1 | VERSANT HIV-1 branched-DNA 3.0 | |||
| 1 | 90 | 70,000 | 52,000 | 24,000 | 780, 580, 250 | B |
| 2 | Positive/<40 | NA | NA | 2,400 | NA, NA, >60 | B |
| 3 | Positive/<40 | 29,000 | 13,000 | 1,200 | >725, >325, >30 | CRF02_AG |
| 4 | 210 | 10,800 | 19,300 | NA | 50, 90, NA | A1 |
| 5 | ND/<40 | ND/<50 | 4.000 | NA | NA, >100, NA | F1 |
| 6 (control) | 3,100 | 3,600 | 2,600 | 8,200 | 1, 1, 3 | B |
| 7 (control) | 3,200 | NA | 1,500 | 1,000 | NA, 0.5, 0.3 | B |
a
All numbers are genome equivalents of HIV-1 RNA per milliliter of plasma. NA, not available; ND, RNA not detected.
b
Degrees of underestimation by the CTM assay compared to results from the Cobas Amplicor Monitor HIV-1 v1.5, Abbott RealTime HIV-1, and VERSANT HIV-1 branched-DNA 3.0 assays, respectively, are shown.
c
Subtype was determined from long terminal repeat, gag, and pol sequences in samples from patients 1, 2, and 3 and the control patients 6 and 7. For patients 4 and 5, sequences of the complete HIV-1 genome were used for subtyping. CRF, circulating recombinant form.